Search research articles
Contact Us
Filters
Showing results (101-110 of 164) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2013
Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors
Patricia LoRusso, Pasi A Jänne, Moacyr Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
Elena Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
Omid Hamid, Dana B Cardin, F Stephen Hodi, et al.
JCO Precision Oncology
|
September 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
Haider Mahdi, Navid Hafez, Deborah Doroshow, et al.
The Oncologist
|
August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
Aditya Bardia, Mrinal Gounder, Jordi Rodon, et al.
Molecular Cancer Therapeutics
|
March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
John H Strickler, Patricia LoRusso, Ravi Salgia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Yoonha Choi, Neekesh V Dharia, Tomi Jun, et al.
Cancer Research Communications
|
March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant Glioma
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2025
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
Jason J Luke, David J Pinato, Dejan Juric, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2019
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 164) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2013
Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors
Patricia LoRusso, Pasi A Jänne, Moacyr Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
Elena Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
Omid Hamid, Dana B Cardin, F Stephen Hodi, et al.
JCO Precision Oncology
|
September 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
Haider Mahdi, Navid Hafez, Deborah Doroshow, et al.
The Oncologist
|
August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
Aditya Bardia, Mrinal Gounder, Jordi Rodon, et al.
Molecular Cancer Therapeutics
|
March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
John H Strickler, Patricia LoRusso, Ravi Salgia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Yoonha Choi, Neekesh V Dharia, Tomi Jun, et al.
Cancer Research Communications
|
March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant Glioma
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2025
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
Jason J Luke, David J Pinato, Dejan Juric, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2019
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, et al.
Page
of 17